Abdou AG, Mostafa AF, Gafar S, et al. - SOX2 was found to be over-expressed in both cutaneous SCC and BCC, with no discernible difference. SOX2 may promote non-melanoma skin cancer progression, as evidenced by its connection with large tumor size and advanced stage.

• There were 24 BCC, 21 SCC, and 26 normal skin specimens studied.

• Normal skin did not express SOX2, but it was upregulated in SCC (85.7%) and BCC (66.7%), with a substantial difference between malignant cases and normal skin.

• However, there was no difference in SOX2 expression between SCC and BCC.

• SOX2 expression was linked to large-sized tumors in all malignant cases (BCC plus SCC) and in SCC alone, as well as its proclivity to be expressed in advanced stages in SCC.